Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers ...

US FDA approves Bristol Myers' blood cancer treatment

By Sneha S K and Siddhi Mahatole Aug 13 (Reuters) - The U.S. FDA on Thursday approved Bristol Myers Squibb's oral combination ...
Morningstar

Bristol Myers Squibb Gets FDA Approval for Myeloma Treatment

Bristol Myers Squibb received approval for Zenbexus to be used as a treatment for multiple myeloma when combined with certain other drugs. The biopharmaceutical manufacturer said Thursday the Food ...

AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'

The companies have discussed a potential merger over several months, reports say.

Lawsuit against Bristol Myers over delayed cancer drug is revived

By Jonathan Stempel NEW YORK, Aug 13 (Reuters) - A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene ...
Seeking Alpha

Bristol Myers Squibb: Strong Pipeline, Weak Outlook (Rating Downgrade)

Bristol-Myers Squibb remains a solid, undervalued investment but is no longer a compelling 'Buy' due to muted growth prospects. BMY's growth portfolio now surpasses its legacy portfolio, yet overall ...

Is the reported $400 billion AstraZeneca-Bristol Myers Squibb megamerger a slam dunk or a disaster waiting to happen?

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.
Hosted on MSN

Cytokinetics sues Bristol-Myers to avoid patent case

Cytokinetics (CYTK) on Thursday disclosed a lawsuit against Bristol-Myers Squibb (BMY) and its 2020 buyout, MyoKardia, to avoid a potential patent infringement case related to its heart disease ...